Hepatitis C Flashcards

(29 cards)

1
Q

acute hepatitis C

A

infection that develops during the first 6 months following the exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

chronic hepatitis C

A

HCV infection that persists beyond 6 months following exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hep C virus pathogen

A

Hepacivirus C
RNA virus
risk of chronic infection depends on hosts ability to clear infection through activation of innate pathway
6 genotypes
reinfection with another HCV genotype is possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

transmission methods

A

parenteral - needle sharing among IVDU, needlestick injury, blood transfusion, dialysis
organ transplantation
sexual - rare in contrast to HBV and HIV
perinatal (vertical)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

risk factors for HCV infection

A

injection drug use
HBV or HIV
Hx of incarceration
recieved blood transfusion or organ transplant before 1992

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

incubation period

A

2 weeks to 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

acute course of disease

A

asymptomatic in 80% of cases
malaise, fever, myalgias, arthralgias
RUQ pain, tender hepatomegaly
nausea, vomitng, diarrhoea
jaundice, possibly pruritis (due to elevated bilirubin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

chronic course of disease

A

seen especially in asymptomatic individuals as treatment may be delayed or not initiated
findings often mild and non specific eg. fatigue
liver cirrhosis
extrahepatic features

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

extrahepatic features of HCV

A

haem: mixed cryoglobulinaemia, lymphoma, immune tyhrombocytopaenic purpura, autoimmune hemolytic anaemia, monoclonal gammopathies
renal - membranoproliferative GN, membranous GN
rheum - polyarteritis nodosa, sjogren syndrome
dermatological - porphyria cutanea tarda, lichen planus
endocrine - T2DM, autoimmune thhyroiditis
vascular - leukocytoclastic vasculitis
other - sialadenitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Hepatitis C tests for people who are HCV naive

A

Anti-HCV antibodies (EIA/ELISA immunoassay): as initial test for immunocompetant individuals who are HCV naive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Hepatitis C tests for people with prior HCV infection or immunocompromise

A

HCV RNA qualitative PCR
after seroconversion from prior HCV infection, HCV antibodies will remain positive for life and have no further diagnostic utility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

why are antibody tests less effective in immunocompromise

A

immunocompromise may prevent people from being able to produce antibodies
seroconversion may be delayed or absent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

interpretation of hepatitis C tests

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how to tell between acute or chronic infection

A

in contrast to Hep A and Hep B infections, there is no serologic or virology assay for HCV that distinguishes between acute and chronic infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how long until antibodies are detectable on immunoassay

A

as long as 6 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

how long until RNA HCV is detectable on qualitative PCR

A

as long as 2-3 weeks

17
Q

laboritory studies for workup

A

quantitative PCR for HCV RNA viral load
routine studies: FBC, UECs
hepatocellular enzymes
cholestasis parameters
liver synthetic function tests
HIV, HAV, HBV for coinfection
serum pregnancy test

18
Q

hepatocellular enzyme changes

A

transaminases (ALT and AST)
are involved in amino acid metabolism and used clinically as parameters of hepatocellular injury
will be normal or raised
fluctuating ALT peaks indicate acute HCV infection

19
Q

cholestasis parameters changes

A

raised GGT
raised alk phos
raised bilirubin

20
Q

liver synthetic function tests

A

alterations indicate cirrhosis
decreased albumin
decreased total protein
increased PT/INR

21
Q

liver biopsy

A

consider if aeitiology of hepatitis is unknown
consider if liver fibrosis staging would alter treatment

22
Q

general principles of treatment

A

the goal of treatment is sustained virological response (SVR)
refer patients with end-stage liver disease for liver transplant evaluation

23
Q

supportive care

A

in all individuals with HCV:
- avoid hepatotoxic drugs and alcohol
- counsel about HIV and hep B prevention
- counsel regarding adherance, reinfection prevention, and medication risks
offer Hep A and B vaccination for Hep A and B seronegative individuals
give harm reduction strategies and refer for treatment for substance abuse for IVDU

24
Q

goals of treatment

A

Hepatitis C is curable and all Australians with hepatitis C should be considered for direct-acting antiviral therapy.

The goals of treatment are:

to prevent cirrhosis, liver failure and hepatocellular carcinoma
to prevent transmission of hepatitis C virus.

25
first line therapy for treatment naive adults
glecaprevir+pibrentasvir for 8 weeks OR sofosbuvir+velpatasvir for 12 weeks
26
what percentage of people clear HCV after acute infection
25%
27
risk factors for development of cirrhosis
longer duration of infection alcohol consumption obesity T2DM co infection with hepatitis B or HIV
28
assessing for the presence of cirrhosis
liver biopsy is gold standard but is rarely used as it is too invasive transient elastography AST to platelet ratio index score
29
confirming cure
test using PCR 12 weeks after completion of treatment in patients with cirrhosis, undertake 6 monthly surveillance for hepatocellular carcinoma